Navigation Links
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Date:7/11/2014

psy." said Douglas Reynolds, President, Sunovion Pharmaceuticals Canada Inc.."Adequate seizure control remains an unmet medical need for a significant number of patients and Sunovion is committed to providing a treatment option to address this need."

About Partial-Onset Seizures
Epilepsy is a chronic neurological condition characterized by recurrent seizures resulting from abnormal firing of impulses from nerve cells in the brain2. In partial-onset seizures, these bursts of electrical activity are initially focused in specific areas of the brain, but may become more widespread, with symptoms varying according to the affected areas3,4.

About APTIOMTM
APTIOMTM, a voltage-gated sodium channel inhibitor, is a prescription medicine approved for use as adjunctive treatment of partial-onset seizures. Treatment with APTIOMTM should be initiated at 400 mg once daily. After one week, dosage may be increased to the recommended maintenance dosage of 800 mg once daily. Some patients may benefit from the maximum recommended maintenance dosage of 1,200 mg once daily, although this dosage is associated with an increase in adverse reactions. The maximum dose of 1,200 mg daily should only be initiated after the patient has tolerated 800 mg daily for at least a week. For some patients, treatment may be initiated at 800 mg once daily if the need for additional seizure reduction outweighs an increased risk of adverse reactions during initiation.  The initial research and development of eslicarbazepine acetate was performed by BIAL, a privately held Portuguese research-based pharmaceutical company. Subsequently, Sunovion acquired the rights under an exclusive license to further develop and commercialize eslicarbazepine acetate in the U.S. and Canadian markets from BIAL. Eslicarbazepine acetate was approved on November 8, 2013, by the U.S. FDA as adjunctive treatment of partial-
'/>"/>

SOURCE Sunovion Pharmaceuticals Canada Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
2. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
8. Avanir Pharmaceuticals to Participate in Two Conferences in December
9. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
10. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
11. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , and ANN ARBOR, Mich. ... small cohort published OncoTargets and Therapy today ... better than Foundation Medicine,s FoundationOne test across a number ... clinically actionable biomarker targets. The purpose of ... commercially available NGS platforms for profiling cancer patients compared ...
(Date:4/28/2015)... DE (PRWEB) April 28, 2015 The ... organizations that work together to lower barriers to innovation ... Ontologies Mapping project. , The Ontologies Mapping project ... establish best practices for ontology management in life sciences ... a set of standardized guidelines, tools and services to ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 More than ... psychosis at some point over the course of their ... symptoms that worsen as the disease progresses. ReachMD ... announces the launch of a series dedicated to PD ... in PD, movement disorders, and psychiatric conditions. , The ...
(Date:4/28/2015)... According to a 2013 report from the American ... from burn injuries per year. Despite several advances in ... scars with subsequent contractures remains a major problem in ... no adequate treatment. Contractures are a permanent tightening of ... permanent deformity. , Synedgen has developed a new ...
Breaking Biology Technology:Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 3Pistoia Alliance Announces Start of Ontologies Mapping Project 2ReachMD Launches Series Focusing on Parkinson’s Disease Psychosis 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3
... Israel, October 4, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... Culex quinquefasciatus mosquito poses a significant threat ... worms and encephalitis-inducing viruses. An international team of scientists, ... SIB Swiss Institute of Bioinformatics sequenced its genome and ... in today,s issue of Science, describe results from comparing ...
... PHILADELPHIA, Oct. 1 Kibow has recently completed a ... a limited number of patients in USA, Canada, Argentina ... just been published in the September issue of the ... Study of Probiotic Dietary Supplementation for Promoting Health Kidney ...
Cached Biology Technology:EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 2EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 3EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 4EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 5EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 6EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 7Major disease-vector mosquito reveals the secrets of its immune system 2Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health 2Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health 3
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... to clean energy needs to be reformed if it ... according to two new articles by Stanford writers. ... massive energy system comes amid taxpayers, $500 million tab ... Solyndra, the global recession, government budget cuts and plunging ...
... and the Max Planck Institute for Evolutionary Anthropology have ... of Congo seem to be more successful than smaller ... The studyconducted over a 12-year period in Nouabal-Ndoki National ... selective pressures that influence the evolution of great apes. ...
... 1, 2012)A recent study published in the May/June 2012 ... journal of the Academy of General Dentistry, found that ... energy drinks, especially among adolescents, is causing irreversible damage ... erode tooth enamel, the glossy outer layer of the ...
Cached Biology News:America's clean energy policies need a reality check, say Stanford researchers 2America's clean energy policies need a reality check, say Stanford researchers 3America's clean energy policies need a reality check, say Stanford researchers 4Bigger gorillas better at attracting mates and raising young 2Sports and energy drinks responsible for irreversible damage to teeth 2
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Biology Products: